098 - CD47 Companies RETURN with Trillium Acquisition! Cassava Sciences DROPS on Accusations

[@Astracygnus]

Thanks for the video

[@syibol7103]

I liked your take on Cassava. I thought it was balanced. I do think the CEO is a sketchy figure. Will see.
Minor suggestion, can you make the slides full screen?

[@breakingbiotech]

Thanks! I did that in my latest episode. It should be easier to see the slides there.

[@syibol7103]

Awesome.
By the way, do you have any thoughts on Heron Therapeutics. HRTX. The short interest is at a crazy high level. I think they have a decent pipeline and with the whole opioid epidemic going on Zynrelef is ought to be a good addition to pain management medicine. I could be missing something though. I wonder if you have covered them before?

[@ElChicharit0]

Regarding the compromised preclinical stuff of SAVA: I think the issue is not whether it's reproducible or not (as you mentioned, a lot of the stuff is not reproducible), but the issue here is that there are obvious signs of figure manipulation. That is definitely done with malicious intent.

[@breakingbiotech]

Agreed. I tried to make that clear.

[@bekincai]

cant wait for CRIS. they have good mono data. buyout next year i think

[@breakingbiotech]

I'm hoping for the same. Good monotherapy effect

[@ciresica86]

30:55 adas cog 11 -- do you this is a good biomarker?

[@breakingbiotech]

It's not so much a biomarker as a cognitive behavior test. Yes, it is among the gold standards for AD cognition evaluation.

[@xdcuff]

Did you hear about Hepion filing patent on the 6th for cancer treatments? Could be really good

[@tarandeepsingh1244]

Seems you are again making a mistake with underestimating Cassava Sciences